Stay alert, beware of scamsters - know more

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open1,559.7
High1,587.6
Low1,557
Prev. Close1,558.9
Avg. Traded Price1,576.14
Volume3,09,237

MARKET DEPTH

info2
Total bid162794.00
Total ask155438.00
OrdersQtyBid
2411583.8
1501583.7
16001583.6
161583.5
51061583.3
AskQtyOrders
1584.25120
1584.36123
1584.4366
1584.56162
1584.64171

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

1554.903 days ago
1610.002 days ago
arrow

LOWER/UPPER CIRCUITS

1411.50
1725.10
arrow
Laurus Labs Limited Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral

Our researchers has found no immediate positive insights for this stock. We'll update this space as soon as we find something.

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 37.47%
Net profit growth 5Y CAGR : 12.4%

STOCK RETURNS

info
Versus Nifty 50
1 w
+1.30%
vs
-0.32%
1 mth
+6.54%
vs
+0.72%
3 mth
+39.75%
vs
-0.73%
6 mth
+55.23%
vs
-4.2%
1 yr
+91.83%
vs
-4.85%
3 yr
+352.42%
vs
+21.53%
5 yr
+143.56%
vs
+51.34%

About the Company

 

Laurus Labs Limited is a research-driven, integrated pharmaceutical company engaged across Contract Development and Manufacturing (CDMO), Generics Finished Dosage Forms (FDF), Active Pharmaceutical Ingredients (APIs), and Biotechnology. Its offerings span development to large-scale manufacturing for pharma, biotech, animal health, crop science and specialty ingredients, supported by state-of-the-art R&D and compliant manufacturing facilities. The company serves a global customer base with products distributed in 80+ countries, with 68 Per cent of revenue from exports and a regional mix of 20 Per cent North America, 25 Per cent Europe and 55 Per cent Rest of World . As on the reporting date, Laurus Labs has 8 subsidiaries (including step-down subsidiaries) .

 

Key milestones and profile highlights:

– Established expertise in complex chemistry and advanced manufacturing, including India’s large Hi-Potent API capabilities and leadership in antiretroviral APIs .

– A diversified portfolio now includes integrated API/FDF development and microbial precision fermentation through its biotech arm .

– 15 development and manufacturing sites and five R&D centres supporting global supply and innovation pipelines .

– Trusted by 250+ global customers, with products distributed in 80+ countries .

 

Business Segments

– Revenue contribution by division (FY25): Generics (API and FDF) 72 Per cent; CDMO 25 Per cent; Biotechnology 3 Per cent .

– Revenue contribution by geography: 68 Per cent exports; 32 Per cent domestic. Regional mix: 20 Per cent North America, 25 Per cent Europe and 55 Per cent Rest of World .

 

Key Management

– Dr. K. Ravindranath – Non-Executive Chairman and Independent Director .

– Dr. Satyanarayana Chava – Executive Director & Chief Executive Officer .

– Mr. V. V. Ravi Kumar – Executive Director & Chief Financial Officer .

– Dr. C. V. Lakshmana Rao – Executive Director – Quality .

– Mr. Krishna Chaitanya Chava – Executive Director – Synthesis .

– Ms. Soumya Chava – Executive Director – Generics .

– G. Venkateswar Reddy – Company Secretary & Compliance Officer .

 

Latest Updates

– Opened a 200,000 sq. ft. small-molecule R&D centre at IKP Knowledge Park, Telangana in September 2024, established with an initial investment of Rs 250 crore, and expected to create employment for over 800 professionals in two years .

– Laurus Bio secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital, with Laurus Labs co-investing Rs 40 crore in December 2024 to expand microbial fermentation capabilities for bio-based proteins and enzymes .

– Formed a joint venture, KRKA Pharma Private Limited, with a 49 Per cent stake; investment of Rs 105.35 crore, accounted as a joint venture with effect from October 03, 2024 .

– Commissioned a new Drug Substance block at Unit-4; Animal Health DS facility (LSLP-U2) made operational (MB-3), with MB-4 under construction; Agrochemicals facility at LSPL Unit-4 brought online .

– Received Establishment Inspection Reports for the Unit 4 API facility and completed 160+ quality audits in FY25 with no critical findings .

– Recognitions: 2024 DET Hurun Award; named among India’s top 75 innovative companies by CII; Export Performance Award at IPHEX; multiple safety and manufacturing excellence awards for Units 1–3 .

personal

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

Yes,Laurus Labs Limited has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 7.20 per share between FY2022 and FY2026, with the most recent dividend of ₹1.20 per share for Apr 26, with an ex-dividend date of 08 May 2026. At the current market price of ₹1,601.20, the trailing dividend yield of Laurus Labs Limited stands at 2.80%.

Over the last 6 months, Laurus Labs Limited has given a return of 60.09%. The stock was priced at ₹1,016.40 on 23 Jan 2026 and has Rise to ₹1,601.20 as of 25 Jul 2026, a change of ₹584.80 per share.

Laurus Labs Limited has delivered a 145.90% absolute return over the past 5 years, equivalent to a CAGR of 19.72% per annum. The stock was priced at ₹651.16 in Jul 2021 and has risen to ₹1,601.20 as of 25 Jul 2026. An investment of ₹1,00,000 in Laurus Labs Limited five years ago would be worth ₹2,45,900.00 today.

Laurus Labs Limited has delivered 91.13% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹1,610.00 on 24 Jul 2026 and a 52-week low of ₹810.05 on 12 Aug 2025. It is currently trading at ₹1,601.20 as of 25 Jul 2026.

The all-time high (ATH) for Laurus Labs Limited was ₹1,601.20, recorded on 24 Jul 2026. At the current price of ₹1,601.20, the stock is trading 0.00% below its all-time high. The all-time low recorded was ₹62.05 on 17 Oct 2019.

Laurus Labs Limited has delivered a return of 42.51% over the last 3 months. The stock was trading at ₹1,113.45 on 24 Apr 2026 and is currently at ₹1,601.20 as of 25 Jul 2026, reflecting a Gain of ₹487.75 per share over this period.

The intraday high for Laurus Labs Limited on the NSE today (25 Jul 2026) was ₹1,610.00. This compares to the 52-week high of ₹1,610.00 recorded on 24 Jul 2026. Today's high was 0.00% above the 52-week high.

For Q1 FY27, Laurus Labs Limited reported: Revenue (Net Sales): ₹17571.60 Cr - Up 11.19% year-on-year from ₹15803.00 Cr in Q4 FY26. Net Income (PAT): ₹2899.60 Cr - Up 51.19% year-on-year from ₹1917.90 Cr in Q4 FY26.

As of 25 Jul 2026, the share price of Laurus Labs Limited is ₹1,601.20 on the NSE and ₹1,608.00 on the BSE. The stock opened at ₹1,560.00, touched a high of ₹1,610.00 and a low of ₹1,554.90 during today's session.

The intraday low for Laurus Labs Limited on the NSE today was ₹1,554.90. The stock's 52-week low stands at ₹810.05, recorded on 12 Aug 2025. Today's low is 91.95% above the 52-week low, indicating the stock is trading well above its yearly lows.

+91
Offer Banner Trigger
Offer Banner

Open a FREE Demat Account

+91